Healthcare -
Biotechnology - NASDAQ - US
$ 0.7298
0.773 %
$ 2.02 M
Market Cap
-0.07
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart PALI
FINANCIALS
Balance Sheet
Palisade Bio, Inc.
| Current Assets | 10.5 M |
| Cash & Short-Term Investments | 9.82 M |
| Receivables | 24 K |
| Other Current Assets | 649 K |
| Non-Current Assets | 386 K |
| Long-Term Investments | 0 |
| PP&E | 87 K |
| Other Non-Current Assets | 299 K |
| Current Liabilities | 3.24 M |
| Accounts Payable | 1.1 M |
| Short-Term Debt | 90 K |
| Other Current Liabilities | 2.04 M |
| Non-Current Liabilities | 152 K |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 152 K |
EFFICIENCY
Earnings Waterfall
Palisade Bio, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 14.9 M |
| Operating Income | -14.9 M |
| Other Expenses | -421 K |
| Net Income | -14.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Palisade Bio, Inc.
| Net Income | -14.4 M |
| Depreciation & Amortization | 3 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 652 K |
| Change in Working Capital | 1.39 M |
| Others | 772 K |
| Free Cash Flow | -12.2 M |
Wall Street Analysts Price Targets
Palisade Bio, Inc.
PALI has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
PALI does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Palisade Bio, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
9.67 K USD 2
9-12 MONTHS
7. News
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108
globenewswire.com
- 1 month ago
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top 10% of all AGA Abstracts Selected for Poster Presentation at DDW
globenewswire.com
- 1 month ago
Palisade Bio (PALI) Upgraded to Buy: What Does It Mean for the Stock?
Palisade Bio (PALI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 1 month ago
Palisade Bio Participates in Virtual Investor “What This Means” Segment
Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC)
globenewswire.com
- 1 month ago
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
Company through its co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108
globenewswire.com
- 1 month ago
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here Carlsbad, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it participated in the Virtual Investor "Top 5 for ‘25” On-Demand Conference . As part of the event, JD Finley, Chief Executive Officer of Palisade Bio, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.
globenewswire.com
- 2 months ago
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
Data presented at the 2025 Crohn's and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients with ulcerative colitis (UC). Palisade Bio presented a poster titled “PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug, Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model” at the Crohn's & Colitis Congress in San Francisco, CA.
globenewswire.com
- 2 months ago
Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress
Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at the Crohn's & Colitis Congress being held February 6-8, 2025 in San Francisco, CA.
globenewswire.com
- 2 months ago
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it had made an equity grant to a new employee under its 2021 Inducement Plan, as amended.
globenewswire.com
- 3 months ago
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board.
globenewswire.com
- 4 months ago
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $5 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 158,000 Class A Units with each unit consisting of (a) one share of common stock and (b) one common warrant to purchase one share of common stock (the “Common Warrants”), and (ii) 3,120,688 Class B Units with each unit consisting of (a) one prefunded common stock purchase warrant to purchase one share of common stock (“Prefunded Warrants”) and (b) one Common Warrant. The price per Class A Unit is $1.525 and the price per Class B Unit is $1.5249 (collectively, the “Offering”).
globenewswire.com
- 4 months ago
What's Going On With Palisade Bio Stock On Thursday?
On Thursday, Palisade Bio Inc PALI stock is trading higher with a strong session volume of 26.97 million, compared to an average volume of 107.68k as per data from Benzinga Pro.
benzinga.com
- 4 months ago
8. Profile
Summary
Palisade Bio, Inc. PALI
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 2.02 M
Dividend Yield
0.00%
Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Contact
5800 Armada Drive, Carlsbad, CA, 92008
https://www.palisadebio.com
IPO
Date
March 30, 2007
Employees
8
Officers
Dr. Joerg Heyer Ph.D.
Head of Translational Science & Medicine
Mr. Ryker Willie
Senior Vice President of Finance & Corporate Controller
Mr. J. D. Finley
Chief Executive Officer, Chief Financial Officer & Director
Dr. Mitchell Lawrence Jones M.D., Ph.D.
Chief Operating Officer & Chief Medical Officer